NEW YORK (GenomeWeb News) – Adaptive Biotechnologies today said that it has received a $2.53 million Phase II Small Business Innovation Research grant to support its adaptive immune system testing technology.

The Seattle-based firm said that it will use the funds, provided by the National Heart, Lung, and Blood Institute, to help commercialize a test that measures the ability of a cancer patient's adaptive immune system to fight infection after a cord blood transplant. Adaptive's test is based on its immunoSEQ next-generation sequencing platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.